DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year financial results at 9:00 a.m. ET on May 9, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking... Read More

AUSTIN, Texas , April 11, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private equity firm, announced today that it has signed a definitive agreement to acquire the dental segment ("HuFriedyGroup" or the "Company") of STERIS plc (NYSE:STE) ("STERIS"). Founded in 1908, HuFriedyGroup is a leading global manufacturer of high-quality instruments, infection prevention products,... Read More

Transaction expected to close in STERIS’s first quarter of fiscal 2025 Divestiture allows STERIS to focus on Customers within core markets Proceeds primarily to be used to repay debt DUBLIN, IRELAND, April 11, 2024 (GLOBE NEWSWIRE) -- ) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has entered into a definitive agreement to divest its Dental segment to Peak Rock Capital, a leading... Read More

Third quarter revenue increases 15% as reported; 10% constant currency organic As reported diluted earnings per share increased to $1.42; adjusted earnings per share increased to $2.22 Fiscal 2024 outlook updated DUBLIN, IRELAND, Feb. 07, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 third quarter ended December 31, 2023. Revenue as reported... Read More

DUBLIN, IRELAND , Jan. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. The dividend is payable on March 22, 2024, to shareholders of record at the close of business on February 23, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available... Read More

DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 third quarter financial results at 9:00 a.m. ET on February 8, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the... Read More

Second quarter revenue growth of 12% as reported and 8% constant currency organic As reported diluted earnings per share increased to $1.16; adjusted earnings increased to $2.03 Fiscal 2024 outlook maintained DUBLIN, IRELAND, Nov. 07, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 second quarter ended September 30, 2023. Revenue as reported... Read More

DUBLIN, IRELAND, Oct. 31, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. The dividend is payable on December 21, 2023, to shareholders of record at the close of business on November 21, 2023. STERIS is a leading global provider of products and services that support patient care with an emphasis on... Read More

DUBLIN, IRELAND, Oct. 24, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 second quarter financial results at 9:00 a.m. ET on November 8, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the... Read More

DUBLIN, IRELAND , Aug. 30, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced that it will participate in the Morgan Stanley Healthcare Conference in New York City on Wednesday, September 13, 2023. Dan Carestio, President and CEO of STERIS will present at 8:10 a.m. Eastern Time. A simultaneous webcast and replay of the Company’s presentation will be available on STERIS’s investor relations... Read More

DUBLIN, IRELAND, Aug. 02, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that it has completed the previously announced acquisition of the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from BD (Becton, Dickinson and Company) (NYSE:BDX). “We are pleased to announce the closing of this acquisition, as the brands we are adding will... Read More

First quarter revenue growth of 11% as reported and constant currency organic As reported diluted earnings per share increased to $ 1. 2 5 ; adjusted earnings increased to $2.0 0 Fiscal 2024 outlook updated to reflect acquisition of BD surgical instrumentation assets DUBLIN, IRELAND, Aug. 01, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024... Read More

DUBLIN, IRELAND , July 26, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. This represents a $0.05 increase in the dividend and the Company’s 18 th consecutive year of dividend growth. The dividend is payable on September 22, 2023, to shareholders of record at the close of business on September 6,... Read More

DUBLIN, IRELAND, July 19, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 first quarter financial results at 9:00 a.m. ET on August 2, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the... Read More

A natural extension for STERIS in the operating room and sterile processing department A primarily consumable s product portfolio Transaction e xpected to close by September 3 0 , 2023 DUBLIN, IRELAND , June 20, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has signed a definitive agreement to purchase the surgical instrumentation, laparoscopic instrumentation... Read More

Fourth quarter as reported revenue increased 14%; 16% constant currency organic revenue growth Fourth quarter as reported earnings per share of $1.88; adjusted EPS of $2.30 Fiscal 2024 Outlook Provided DUBLIN, IRELAND , May 10, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 fourth quarter and full year ended March 31, 2023. Revenue as reported... Read More

DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. “We are pleased to welcome Dr. Alegria to our Board,” said Mohsen Sohi, Chairman of STERIS. “She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition.”... Read More

DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that STERIS's Board of Directors has authorized a new share buyback program for the purchase of up to $500 million of the Company's ordinary shares. Shares may be repurchased from time to time through open market transactions, including 10b5-1 plans. The repurchase program may be suspended or discontinued at... Read More

DUBLIN, IRELAND, April 24, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 fourth quarter and full year financial results at 9:00 a.m. ET on May 11, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking... Read More

As reported revenue increased 1%; 7% constant currency organic revenue growth As reported earnings per share of $1.24; adjusted EPS of $2.02 Updated outlook provided DUBLIN, IRELAND, Feb. 08, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 third quarter ended December 31, 2022. Revenue as reported for the quarter increased 1% to $1.22 billion... Read More

DUBLIN, IRELAND, Feb. 01, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.47 per share. The dividend is payable March 23, 2023 to shareholders of record at the close of business on February 24, 2023. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection... Read More

DUBLIN, IRELAND, Jan. 25, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 third quarter financial results at 10:00 a.m. ET on February 9, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the... Read More